Vertex drops $10B on Crinetics — meanwhile, your $CRNX just got rekt to the offer price 💊

Crinetics Pharmaceuticals shares nearly doubled on Monday, July 6 after Vertex Pharmaceuticals agreed to acquire the company for $10 billion in cash, with Vertex set to pay $85 per share. That figure is roughly double Crinetics' closing price the day before the deal was announced. William Blair analyst Myles Minter called the price tag defensible if commercial expectations are met. "Investors will debate this (stock was down 1.8% after hours), but we view this as reasonable if the peak sales number can be achieved," Minter said.

Vertex is buying Crinetics primarily for Palsonify, a once-daily oral pill for acromegaly, a rare disorder caused by excess growth hormone. Patients previously relied on regular injections, positioning the pill as a convenience upgrade in a market Vertex expects to anchor with a second late-stage asset for another rare hormone condition. Vertex, best known for its cystic fibrosis drugs, has projected combined peak sales of more than $5 billion a year for the two products.

Retail sentiment on Crinetics shifted from bearish to bullish within a day of the announcement, a rapid mood swing mirrored in past buyout-driven moves such as the GameStop eBay takeover saga. Once a cash buyout is announced, shares typically trade toward the agreed price rather than on independent fundamentals, and Crinetics was already trading near the $85 target following the announcement.

The remaining upside is limited to a small gap to the offer price and the risk that the transaction fails to close before the expected third-quarter completion, a pattern also seen in deals like the Riot Platforms Bitfarms takeover, where shares converged near the offer price shortly after the deal was announced.